AusCann Group Holdings Past Earnings Performance
Past criteria checks 0/6
AusCann Group Holdings's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 31.2% annually. Revenues have been growing at an average rate of 50.2% per year.
Key information
-3.6%
Earnings growth rate
10.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 50.2% |
| Return on equity | -137.4% |
| Net Margin | -1,224.0% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How AusCann Group Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 2 | -25 | 3 | 0 |
| 31 Mar 22 | 2 | -17 | 3 | 0 |
| 31 Dec 21 | 2 | -9 | 4 | 0 |
| 30 Sep 21 | 2 | -10 | 4 | 0 |
| 30 Jun 21 | 2 | -11 | 5 | 0 |
| 31 Dec 20 | 1 | -8 | 5 | -1 |
| 30 Sep 20 | 1 | -7 | 5 | 0 |
| 30 Jun 20 | 1 | -7 | 5 | 0 |
| 31 Mar 20 | 1 | -7 | 5 | 0 |
| 31 Dec 19 | 1 | -7 | 5 | 0 |
| 30 Sep 19 | 1 | -7 | 4 | 0 |
| 30 Jun 19 | 1 | -8 | 4 | 0 |
| 31 Mar 19 | 0 | -7 | 4 | 0 |
| 31 Dec 18 | 0 | -7 | 5 | 1 |
| 30 Sep 18 | 0 | -7 | 6 | 0 |
| 30 Jun 18 | 0 | -8 | 7 | 0 |
| 31 Mar 18 | 0 | -13 | 8 | 0 |
| 31 Dec 17 | 0 | -18 | 9 | 0 |
| 30 Sep 17 | 0 | -16 | 8 | 0 |
| 30 Jun 17 | 0 | -14 | 6 | 0 |
| 31 Mar 17 | 0 | -11 | 7 | 0 |
| 31 Dec 16 | 0 | -7 | 7 | 0 |
| 30 Sep 16 | 0 | -6 | 6 | 0 |
Quality Earnings: AC8 is currently unprofitable.
Growing Profit Margin: AC8 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AC8 is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare AC8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AC8 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10%).
Return on Equity
High ROE: AC8 has a negative Return on Equity (-137.39%), as it is currently unprofitable.